 |
Joint
Care eNews #4 / NIH GAIT |
| Joint Care Headlines | ||||
| NIH
GAIT Study - Encouraging data on the efficacy of the combination
Chondroitin and Glucosamine The results of the study, presented during the American College of Rheumatism (ACR) Meeting, are highly relevant on a scientific level as this was a large-scale clinical trial carried out by a completely independent organisation (the US National Institute of Health - NIH). CS TM Bio-Active, Bioiberica's chondroitin sulfate, was chosen by the NIH for use in this study because of its high standards of quality and safety and its science behind. (more) NIH GAIT Study - Chondroitin effective in Joint Swelling and K-L Grade 2 OA New data from the NIH study reveal the efficacy of Chondroitin Sulfate in joint swelling as well as its differential effect on Osteoarthritis Symptoms related to degree of Radiographic Involvement. (more) |
||||
|
| ||||
| Joint Care News | ||||
| NIH GAIT Study - Encouraging data on the efficacy of
the combination Chondroitin and Glucosamine The results of the study, presented during the American College of Rheumatism (ACR) Meeting, are highly relevant on a scientific level as this was a large-scale clinical trial carried out by a completely independent organisation (the US National Institute of Health - NIH). CS TM Bio-Active, Bioiberica's chondroitin sulfate, was chosen by the NIH for use in this study because of its high standards of quality and safety and its science behind. The encouraging results were highlighted at the conclusion of the abstract published by the ACR: "Combination Glucosamine (G) Chondroitin Sulfate (CS) is effective in treating moderate to severe knee pain due to OA". Even though the primary outcome of the study showed that in the overall population the positive response to G and CS was not statistically significant, further exploratory analysis evidence conclusive data that show the efficacy of this agents in various sub-groups of patients. In fact, 79.2% of patients with moderate to severe pain responded positively to treatment with Chondroitin Sulfate and Glucosamine in combination, exceeding not only placebo (54.3 %) but also Celecoxib (69.4%) the reference drug or positive control. According to scientists, these data show that there are sub-groups of OA patients who, depending on pain, functional disability, degree of radiological OA, etc. do not always respond to the same treatment in the same way. In the discussion of the results, the investigators highlighted limitations of the study such as the high placebo effect observed and the difficulty of detecting improvement among patients with little pain. (top) NIH GAIT Study - Chondroitin effective in Joint Swelling and K-L Grade 2 OA New data from the NIH study reveal the efficacy of Chondroitin Sulfate in joint swelling as well as its differential effect on Osteoarthritis Symptoms related to degree of Radiographic Involvement. The results were presented by Dr. Clegg, the main researcher of the NIH study, at the OARSI Osteoarthritis World Conference and the CME Symposium on Chondroitin Sulfate which took place during the ACR Annual Scientific Meeting. LINK According to the data presented, Chondroitin Sulfate was the only treatment effective in reducing joint swelling . Joint swelling is brought about by an increase of fluid in the joint space and involves swelling of the joint, pain and functional disability. It is a very common condition among people suffering from OA , and occurs in about 50% of cases. These results also confirm the efficiency of Chondroitin Sulfate in patients suffering from K-L grade 2 knee osteoarthritis, that is with radiological degrees of initial OA , when there is not yet any structural damage to the joint. The data are statistically significant for functional capacity and stiffness. This response is similar to that achieved with Celecoxib. Once more, it was shown that there are sub-groups of OA patients and that Chondroitin Sulfate is an effective treatment for OA . As always, more clinical studies are required to confirm the results observed. (top) |
||||
| Short News | ||
| Publication
of the NIH Study The results of the NIH study are expected to be published in the New England Journal of Medicine within the first quarter of 2006. New England Journal Medicine Chondroitin Symposium The CME Symposium on Chondroitin Sulfate which took place following the ACR Meeting was highly successful, attracting a large attendance by participating physicians. It was also outstanding because of the high level demonstrated by the speakers who presented new data explaining the efficacy of Chondroitin Sulfate on both a symptomatic and structural level. 4 new studies in the OARSI Congress Bioiberica presented four new scientific studies on the efficacy of its products at the 10th World Congress on Osteoarthritis - OARSI (Osteoarthritis Research Society International) Boston, USA, 8-11 dec. 2005. OARSI |
||
| Latest eNews | ||
| You can read previous numbers of Joint Care
eNews online at our website: Number 1 Number 2 Number 3 |
||
| Our Products | ||
 | ||
 |
||
 |
||
| If
you don't want to receive any further Joint Care eNews,
please click here to unsubscribe. |
Bioiberica SA follows the Spanish Organic Law 15, 13th of Dec 1999. According to the Spanish organic law of data protection we are obliged to communicate to you that any data that you may provide to us by telephone or written will remain totally confidential in the DB of Bioiberica SA and it will only be used by Bioiberica SA, until you tell us not to continue doing so. You will always have the right to modify any of your data at any time. | ||||
 |
|
||||||||